Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients

MLA

Alessandra Santini, et al. “Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients.” American Journal of Clinical Oncology, vol. 41, Nov. 2018, pp. 1101–05. EBSCOhost, https://doi.org/10.1097/coc.0000000000000428.

APA

Alessandra Santini, Carlotta Giorgi, Francesco Fiorica, Antonio Frassoldati, Lorenzo Belluomini, Benedetta Urbini, & Antonio Stefanelli. (2018). Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients. American Journal of Clinical Oncology, 41, 1101–1105. https://doi.org/10.1097/coc.0000000000000428

Chicago

Alessandra Santini, Carlotta Giorgi, Francesco Fiorica, Antonio Frassoldati, Lorenzo Belluomini, Benedetta Urbini, and Antonio Stefanelli. 2018. “Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients.” American Journal of Clinical Oncology 41 (November): 1101–5. doi:10.1097/coc.0000000000000428.